Table 2 |
||
|
Median survival based on Eag and HERG immunoreactivity and other prognostic markers. |
||
|
Median survival, Months(IQR) |
P (log rank) |
|
|
|
||
|
Eag staining |
||
|
|
||
|
Low/Intermediate |
24.1 (18.9-29.2) |
|
|
|
||
|
High |
13.8 (7.2-20.3) |
0.016 |
|
|
||
|
|
||
|
HERG staining |
||
|
|
||
|
Low/Intermediate |
22.4 (14.1-30.6) |
|
|
|
||
|
High |
16.4 (9.7-23.0) |
0.586 |
|
|
||
|
|
||
|
Stage |
||
|
|
||
|
1 |
137.6 (48.8-226.3) |
|
|
|
||
|
2 |
28.4 (4.8-51.9) |
|
|
|
||
|
3 |
13.0 (9.0-16.9) |
|
|
|
||
|
4 |
7.3 (0-15.2) |
< 0.001 |
|
|
||
|
|
||
|
Grade |
||
|
|
||
|
G1 |
28.9 (17.2-40.5) |
|
|
|
||
|
G2 |
33.1 (16.4-49.7) |
|
|
|
||
|
G3 |
16.0 (13.0-18.9) |
0.001 |
|
|
||
|
|
||
|
Residual disease |
||
|
|
||
|
No macroscopic disease (Optimal debulking) |
65.2 (37.5-92.8) |
|
|
|
||
|
Macroscopic disease |
10.7 (7.6-13.7) |
< 0.001 |
|
|
||
|
|
||
|
Histological type |
||
|
|
||
|
Serous |
17.3 (12.6-21.9) |
|
|
|
||
|
Mucinous |
30.7 (0-64.7) |
< 0.001 |
|
|
||
|
Endometriod |
26.6 (5.3-47.8) |
|
|
|
||
|
Clear cell |
155 (89.7-222) |
|
|
|
||
|
Undifferentiated |
13.3(5.3-21.2) |
|
|
|
||
|
|
||
|
Adjuvant Chemotherapy |
||
|
|
||
|
Yes |
20.3 (15.4-25.1) |
|
|
|
||
|
No |
18.8 (0.6-36.9) |
0.04 |
|
|
||
|
Asher et al. Diagnostic Pathology 2010 5:78 doi:10.1186/1746-1596-5-78 |
||
